Advertisement

Infection

pp 1–8 | Cite as

In vitro efficacy of phytotherapeutics suggested for prevention and therapy of urinary tract infections

  • Julian Marcon
  • Sören Schubert
  • Christian G. Stief
  • Giuseppe MagistroEmail author
Original Paper

Abstract

Purpose

To analyse the therapeutic efficacy of various phytotherapeutics and their antimicrobial compounds with regard to strain specificity and dose dependence.

Methods

A representative strain collection of 40 uropathogenic bacteria isolated from complicated and uncomplicated urinary tract infection was subjected to various virulence assays (bacterial growth, mannose-sensitive agglutination, and motility) to determine the therapeutic impact of various compounds with antimicrobial activity. We tested proanthocyanidins (PAC), d-mannose, rosemary extract (Canephron®), and isothiocyanates (Angocin®).

Results

d-mannose efficiently blocked the adhesive properties of all type 1 fimbriae-positive isolates in low concentration (0.2%), but showed no bacteriostatic effect. PAC also actively blocked agglutination, but the concentration varied considerably among isolates. Escherichia coli required the highest concentration (10%), while Enterobacter cloacae responded to low concentrations (0.1%). Allyl isothiocyanates not only impaired agglutination in all tested isolates, but also had a dramatic impact on flagella-mediated motility in Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis (p < 0.001). The administration of rosemary extracts revealed a strong bacteriostatic effect in growth assays. All tested strains were strongly inhibited by the addition of 10 μg/ml or 1 μg/ml of purified rosemary extractions with the exception of Serratia marcescens. Morganella morganii responded only to 10 μg/ml.

Conclusion

Phytotherapeutics and small-molecular compounds like mannosides have the potential to become an integral part in a multi-modal treatment concept for the treatment and prevention of urinary tract infections. Their efficiency can be optimised when strain specificities and therapeutic concentrations are taken into account.

Keywords

Urinary tract infections Phytotherapeutics Prevention Therapy Uropathogenic Escherichia coli (UPEC) 

Notes

Author contributions

JM: project development, data collection and analysis, and manuscript writing. SS: supervision. CGS: project development and supervision. GM: project development, data collection and analysis, and manuscript writing.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    O’Neill J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Rev Antimicrob Resist. 2014;1:1–16.Google Scholar
  2. 2.
    Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13:269–84.CrossRefGoogle Scholar
  3. 3.
    Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. J Infect Dis. 2001;183:S1–4.CrossRefGoogle Scholar
  4. 4.
    Litwin MS, Saigal CS, Yano EM, Avila C, Geschwind SA, Hanley JM, et al. Urologic diseases in America Project: analytical methods and principal findings. J Urol. 2005;173:933–7.CrossRefGoogle Scholar
  5. 5.
    Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol. 2010;7:653–60.CrossRefGoogle Scholar
  6. 6.
    Tandogdu Z, Cek M, Wagenlehner F, Naber K, Tenke P, van Ostrum E, et al. Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the global prevalence of infections in urology study. World J Urol. 2014;32:791–801.Google Scholar
  7. 7.
    Grabe MJ, Resman F. Antimicrobial stewardship: what we all just need to know. Eur Urol Focus. 2018;5:46–9.CrossRefGoogle Scholar
  8. 8.
    Magistro G. Urological infections: “the time for change is now”. Eur Urol Focus. 2018;5:1.Google Scholar
  9. 9.
    Magistro G, Stief CG. Vaccine Development for urinary tract infections: where do we stand? Eur Urol Focus. 2018;5:39–41.CrossRefGoogle Scholar
  10. 10.
    Naber KG, Wagenlehner FME. Novel antibiotics in the treatment of urinary tract infections. Eur Urol Focus. 2018;5:10–2.CrossRefGoogle Scholar
  11. 11.
    Pilatz A, Veeratterapillay R, Koves B, Cai T, Bartoletti R, Wagenlehner F, et al. Update on strategies to reduce infectious complications after prostate biopsy. Eur Urol Focus. 2018;5:20–8.CrossRefGoogle Scholar
  12. 12.
    Bonkat G, Bartoletti R, Cai T, Bruyere F, et al. EAU guidelines on urological infections. Edn. presented at the EAU Annual Congress Copenhagen 2018. ISBN 978-94-92671-01-1.Google Scholar
  13. 13.
    Beerepoot MA, Geerlings SE, van Haarst EP, van Charante NM, ter Riet G. Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials. J Urol. 2013;190:1981–9.CrossRefGoogle Scholar
  14. 14.
    Smith AL, Brown J, Wyman JF, Berry A, Newman DK, Stapleton AE. Treatment and prevention of recurrent lower urinary tract infections in women: a rapid review with practice recommendations. J Urol. 2018;200:1174–91.CrossRefGoogle Scholar
  15. 15.
    Jepson RG, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2008;10:CD001321.Google Scholar
  16. 16.
    Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2012;10:001321.Google Scholar
  17. 17.
    Magistro G, Hoffmann C, Schubert S. The salmochelin receptor IroN itself, but not salmochelin-mediated iron uptake promotes biofilm formation in extraintestinal pathogenic Escherichia coli (ExPEC). Int J Med Microbiol. 2015;305:435–45.CrossRefGoogle Scholar
  18. 18.
    Magistro G, Magistro C, Stief CG, Schubert S. The high-pathogenicity island (HPI) promotes flagellum-mediated motility in extraintestinal pathogenic Escherichia coli. PLoS One. 2017;12:e0183950.CrossRefGoogle Scholar
  19. 19.
    Schembri MA, Sokurenko EV, Klemm P. Functional flexibility of the FimH adhesin: insights from a random mutant library. Infect Immun. 2000;68:2638–46.CrossRefGoogle Scholar
  20. 20.
    Nielubowicz GR, Mobley HL. Host-pathogen interactions in urinary tract infection. Nat Rev Urol. 2010;7:430–41.CrossRefGoogle Scholar
  21. 21.
    Hannan TJ, Totsika M, Mansfield KJ, Moore KH, Schembri MA, Hultgren SJ. Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol Rev. 2012;36:616–48.CrossRefGoogle Scholar
  22. 22.
    de Oliveira JR, de Jesus D, Figueira LW, de Oliveira FE, Pacheco Soares C, Camargo SE, et al. Biological activities of Rosmarinus officinalis L. (rosemary) extract as analyzed in microorganisms and cells. Exp Biol Med (Maywood). 2017;242:625–34.CrossRefGoogle Scholar
  23. 23.
    Taylor SN, Marrazzo J, Batteiger BE, Hook EW 3rd, Sena AC, Long J, et al. Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea. N Engl J Med. 2018;379:1835–45.CrossRefGoogle Scholar
  24. 24.
    Giacobbe DR, Mikulska M, Viscoli C. Recent advances in the pharmacological management of infections due to multidrug-resistant Gram-negative bacteria. Expert Rev Clin Pharmacol. 2018;11:1219–36.CrossRefGoogle Scholar
  25. 25.
    Aziminia N, Hadjipavlou M, Philippou Y, Pandian SS, Malde S, Hammadeh MY. Vaccines for the prevention of recurrent urinary tract infections: a systematic review. BJU Int. 2018;123:753–68.CrossRefGoogle Scholar
  26. 26.
    Huttner A, Hatz C, van den Dobbelsteen G, Abbanat D, Hornacek A, Frolich R, et al. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. Lancet Infect Dis. 2017;17:528–37.CrossRefGoogle Scholar
  27. 27.
    Cusumano CK, Pinkner JS, Han Z, Greene SE, Ford BA, Crowley JR, et al. Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Sci Transl Med. 2011;3:109ra15.CrossRefGoogle Scholar
  28. 28.
    Klein T, Abgottspon D, Wittwer M, Rabbani S, Herold J, Jiang X, et al. FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. J Med Chem. 2010;53:8627–41.CrossRefGoogle Scholar
  29. 29.
    Kranjcec B, Papes D, Altarac S. d-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2014;32:79–84.CrossRefGoogle Scholar
  30. 30.
    Wagenlehner FM, Abramov-Sommariva D, Holler M, Steindl H, Naber KG. Non-antibiotic herbal therapy (BNO 1045) versus antibiotic therapy (fosfomycin trometamol) for the treatment of acute lower uncomplicated urinary tract infections in women: a double-blind, parallel-group, randomized, multicentre, non-inferiority phase III trial. Urol Int. 2018;101:327–36.CrossRefGoogle Scholar
  31. 31.
    Sabadash MS. Canephron® N in the treatment of recurrent cystitis in women of child-bearing age: a randomised controlled study. Clin Phytosci. 2017;3:9.CrossRefGoogle Scholar
  32. 32.
    Albrecht U, Goos KH, Schneider B. A randomised, double-blind, placebo-controlled trial of a herbal medicinal product containing Tropaeoli majoris herba (Nasturtium) and Armoraciae rusticanae radix (Horseradish) for the prophylactic treatment of patients with chronically recurrent lower urinary tract infections. Curr Med Res Opin. 2007;23:2415–22.CrossRefGoogle Scholar
  33. 33.
    Lau I, Albrecht U, Kirschner-Hermanns R. Phytotherapy in catheter-associated urinary tract infection: observational study recording the efficacy and safety of a fixed herbal combination containing Tropaeoli majoris herba and Armoraciae rusticanae radix. Urologe A. 2018;57:1472–80.CrossRefGoogle Scholar
  34. 34.
    Lane MC, Alteri CJ, Smith SN, Mobley HL. Expression of flagella is coincident with uropathogenic Escherichia coli ascension to the upper urinary tract. Proc Natl Acad Sci USA. 2007;104:16669–74.CrossRefGoogle Scholar
  35. 35.
    Lane MC, Lockatell V, Monterosso G, Lamphier D, Weinert J, Hebel JR, et al. Role of motility in the colonization of uropathogenic Escherichia coli in the urinary tract. Infect Immun. 2005;73:7644–56.CrossRefGoogle Scholar
  36. 36.
    Wright KJ, Seed PC, Hultgren SJ. Uropathogenic Escherichia coli flagella aid in efficient urinary tract colonization. Infect Immun. 2005;73:7657–68.CrossRefGoogle Scholar
  37. 37.
    Kaiser SJ, Mutters NT, Blessing B, Gunther F. Natural isothiocyanates express antimicrobial activity against developing and mature biofilms of Pseudomonas aeruginosa. Fitoterapia. 2017;119:57–63.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of UrologyLudwig-Maximilians-UniversityMunichGermany
  2. 2.Max von Pettenkofer-Institut für Hygiene und Medizinische MikrobiologieMunichGermany

Personalised recommendations